Xencor (XNCR) Cash & Current Investments (2013 - 2026)
Xencor (XNCR) posted quarterly Cash & Current Investments of $384.4 million for Q1 2026, up 334.1% year-over-year from $88.5 million in Q1 2025, and down 11.68% quarter-over-quarter from $435.2 million in Q4 2025.
Analysis
Xencor (XNCR) Cash & Current Investments (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported Cash & Current Investments for 14 consecutive years, with $384.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments rose 334.1% year-over-year to $384.4 million; the TTM figure through Mar 2026 stood at $384.4 million (up 334.1% YoY), while the FY2025 annual figure was $435.2 million, down 3.25% from the prior year.
- Cash & Current Investments fell to $384.4 million in Q1 2026 per XNCR's latest filing, from $435.2 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $551.5 million in Q4 2023 and bottomed at $59.0 million in Q2 2024.
- Historically, Cash & Current Investments has averaged $238.0 million across 5 years, with a median of $112.1 million in 2023.
- Annual changes were most pronounced in 2022 — Cash & Current Investments sank 79.54% — and 2025, when it soared 583.32%.
- Xencor's Cash & Current Investments stood at $96.4 million in 2022, then soared by 472.27% to $551.5 million in 2023, then slipped by 18.43% to $449.8 million in 2024, then retreated by 3.25% to $435.2 million in 2025, then fell by 11.68% to $384.4 million in 2026.
- Business Quant data shows XNCR's Cash & Current Investments at $384.4 million in Q1 2026, $435.2 million in Q4 2025, and $112.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.14 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 836.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 377.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 377.82 Mn |
| Mar 31, 2026 | 384.38 Mn |
| Dec 31, 2025 | 435.23 Mn |
| Sep 30, 2025 | 386.78 Mn |
| Jun 30, 2025 | 403.43 Mn |
| Mar 31, 2025 | 420.70 Mn |
| Dec 31, 2024 | 449.85 Mn |
| Sep 30, 2024 | 464.07 Mn |
| Jun 30, 2024 | 480.14 Mn |
| Mar 31, 2024 | 491.40 Mn |
| Dec 31, 2023 | 551.52 Mn |
| Sep 30, 2023 | 465.56 Mn |
| Jun 30, 2023 | 511.38 Mn |
| Mar 31, 2023 | 548.32 Mn |
| Dec 31, 2022 | 580.63 Mn |
| Sep 30, 2022 | 568.05 Mn |
| Jun 30, 2022 | 485.03 Mn |
| Mar 31, 2022 | 356.33 Mn |
| Dec 31, 2021 | 297.25 Mn |
| Sep 30, 2021 | 240.62 Mn |